WellStar Cancer Network 2016 Annual Report

Despite evidence suggesting the role of
adjuvant endocrine therapy in lowering
the risk of tumor recurrence, many female
patients who should be receiving this
therapy are not. This measure assesses
whether patients with a certain stage of
breast cancer (IC through IIIC) and ER/PR+
are currently receiving the therapy. There
are allowable medical, patient and system
reasons to document instances in which a
woman with stage IC through IIIC, ER/PR+
may not be a candidate for the therapy.
Source: National Quality Forum
100
80
60
40
20
Hormone Therapy for Hormone
Receptor Positive Breast Cancer
0
93%
WellStar
90%
Benchmark
Benchmark: NCBC , CP3R Expected Performance
Hillary Hahm, M.D., Ph.D.
Breast Sub Committee Chair
100
80
60
40
20
0
Combination Chemotherapy
for Hormone Receptor
Negative Breast Cancer
100%
WellStar
90%
Benchmark
Benchmark: CP3R Expected Performance
There is extensive documentation of the
benefit of multi-agent chemotherapy in
women with hormone receptor negative
breast cancer. Chemotherapy reduces
the risk of distant disease recurrence and
death by about one-third. The restriction
to women under age 70 is because
this measure is for the purpose of
provider accountability. There are limited
data in women over age 70 to guide
recommendations, and a higher fraction
of these women have reasons to omit
chemotherapy, including co-morbidity.
Source: National Quality Forum
Lisa Sherman, BSN, RN
Breast Nurse Navigator
Sara Owens, BSN, RN
Breast Nurse Navigator
WELLSTAR CANCER NETWORK • 2016 ANNUAL REPORT • 11